PHAXIAM Therapeutics (PHXM) Competitors $3.10 0.00 (0.00%) As of 08/19/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsTrendsBuy This Stock PHXM vs. XCUR, EGRX, RENB, EQ, CALC, HYPD, AADI, LVTX, SNTI, and KLTOShould you be buying PHAXIAM Therapeutics stock or one of its competitors? The main competitors of PHAXIAM Therapeutics include Exicure (XCUR), Eagle Pharmaceuticals (EGRX), Renovaro (RENB), Equillium (EQ), CalciMedica (CALC), Hyperion DeFi (HYPD), Aadi Bioscience (AADI), LAVA Therapeutics (LVTX), Senti Biosciences (SNTI), and Klotho Neurosciences (KLTO). These companies are all part of the "pharmaceutical products" industry. PHAXIAM Therapeutics vs. Its Competitors Exicure Eagle Pharmaceuticals Renovaro Equillium CalciMedica Hyperion DeFi Aadi Bioscience LAVA Therapeutics Senti Biosciences Klotho Neurosciences PHAXIAM Therapeutics (NASDAQ:PHXM) and Exicure (NASDAQ:XCUR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment. Does the media prefer PHXM or XCUR? In the previous week, Exicure had 2 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 2 mentions for Exicure and 0 mentions for PHAXIAM Therapeutics. Exicure's average media sentiment score of 0.99 beat PHAXIAM Therapeutics' score of 0.00 indicating that Exicure is being referred to more favorably in the news media. Company Overall Sentiment PHAXIAM Therapeutics Neutral Exicure Positive Do institutionals & insiders have more ownership in PHXM or XCUR? 0.4% of PHAXIAM Therapeutics shares are held by institutional investors. Comparatively, 42.8% of Exicure shares are held by institutional investors. 1.9% of PHAXIAM Therapeutics shares are held by insiders. Comparatively, 3.9% of Exicure shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is PHXM or XCUR more profitable? PHAXIAM Therapeutics' return on equity of 0.00% beat Exicure's return on equity.Company Net Margins Return on Equity Return on Assets PHAXIAM TherapeuticsN/A N/A N/A Exicure N/A -192.16%-84.30% Which has stronger valuation & earnings, PHXM or XCUR? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPHAXIAM TherapeuticsN/AN/A-$240KN/AN/AExicureN/AN/A-$9.70M-$3.88-1.61 Which has more risk and volatility, PHXM or XCUR? PHAXIAM Therapeutics has a beta of 2.35, suggesting that its share price is 135% more volatile than the S&P 500. Comparatively, Exicure has a beta of 3.67, suggesting that its share price is 267% more volatile than the S&P 500. SummaryExicure beats PHAXIAM Therapeutics on 5 of the 8 factors compared between the two stocks. Get PHAXIAM Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PHXM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PHXM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHXM vs. The Competition Export to ExcelMetricPHAXIAM TherapeuticsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.58M$139.24M$5.75B$9.60BDividend YieldN/A3.74%4.54%4.09%P/E RatioN/A3.9030.4025.01Price / SalesN/A4,101.27415.24176.62Price / CashN/A13.1937.3459.16Price / Book0.3948.408.956.28Net Income-$240K-$90.99M$3.26B$265.47M7 Day PerformanceN/A2.00%-0.19%-2.06%1 Month PerformanceN/A5.71%3.83%0.32%1 Year PerformanceN/A185.22%28.78%20.75% PHAXIAM Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58MN/A0.0049XCURExicure2.1164 of 5 stars$6.65-2.9%N/A+1,538.6%$42.03M$500K-1.7150Short Interest ↓EGRXEagle Pharmaceuticals1.7968 of 5 stars$3.20flatN/A-43.5%$41.56M$257.55M0.00100Gap DownRENBRenovaro1.253 of 5 stars$0.24+0.5%N/A-65.1%$41.15MN/A-0.3120Short Interest ↓EQEquillium0.9232 of 5 stars$1.14+16.3%$3.00+163.2%+53.8%$40.72M$41.10M-2.9240Earnings ReportShort Interest ↓Gap DownCALCCalciMedica3.3904 of 5 stars$2.91+11.5%$16.00+449.8%-33.8%$40.65MN/A-1.8230News CoverageShort Interest ↓Gap UpHYPDHyperion DeFi0.5756 of 5 stars$7.20+7.6%$2.00-72.2%-90.0%$40.32M$60K-0.1240Earnings ReportGap UpAADIAadi Bioscience0.5492 of 5 stars$1.62-5.3%$1.67+2.9%+3.2%$40.01M$25.07M-0.7140LVTXLAVA Therapeutics1.8144 of 5 stars$1.52-1.3%$2.69+76.6%-16.2%$39.99M$11.98M-1.4560Earnings ReportShort Interest ↓SNTISenti Biosciences2.9149 of 5 stars$1.52-0.7%$8.50+459.2%-24.2%$39.76M$2.56M-0.174Analyst UpgradeShort Interest ↓KLTOKlotho NeurosciencesN/A$0.86+10.4%N/AN/A$39.61MN/A-2.39N/AEarnings Report Related Companies and Tools Related Companies Exicure Competitors Eagle Pharmaceuticals Competitors Renovaro Competitors Equillium Competitors CalciMedica Competitors Hyperion DeFi Competitors Aadi Bioscience Competitors LAVA Therapeutics Competitors Senti Biosciences Competitors Klotho Neurosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHXM) was last updated on 8/20/2025 by MarketBeat.com Staff From Our PartnersWashington Thinks They Own Your Bank AccountWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredSilver’s Still Under $35… For Now.Silver is trading around $33—but insiders are betting on a $70 breakout by year’s end. With supply shrinkin...GoldenCrest Metals | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored"I'm risking my reputation on this"A massive supply shock is building in the crypto market that could send Bitcoin to $300,000 this year. That...Crypto 101 Media | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PHAXIAM Therapeutics S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share PHAXIAM Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access